A new hemagglutination method for blood grouping

一种新的血凝方法

基本信息

批准号：
8833912
负责人：
Simon Bystryak
金额：
$ 49.52万
依托单位：
ALLIED INNOVATIVE SYSTEMS, LLC
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-02-01 至 2017-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8833912
关键词：
Affect Agglutination Agglutination Tests Antibodies Automation Binding Biological Biological Assay Blood Blood Banks Blood Screening Blood Tests Blood donor Blood specimen Blood typing procedure Businesses Cells Centrifugation Clinical Clinics and Hospitals Communities Complex D Cells Detection Development Devices Economics Elements Erythrocytes Frequencies Goals Grouping Hemagglutination Hemagglutination test Hepatitis B e Antigens Hospitals Immunoassay Individual Isoantibodies K antigen Laboratories Latex Legal patent Licensing Manuals Methods One-Step dentin bonding system Optics Patient Care Performance Phase Process Production Public Health Reaction Reading Reagent Reproducibility Research Sampling System Techniques Technology Test Result Testing Time Ultrasonics Ultrasonography Validation Variant accelerated particle base blood group cost design improved innovation instrumentation method development new technology novel particle prototype public health relevance quantitative ultrasound rapid technique

项目摘要

DESCRIPTION (provided by applicant): The long-term goal of the proposed research is to develop a novel quantitative particle agglutination technology for improving the performance of blood typing assays. The conventional hemagglutination blood typing assays have serious drawbacks such as limited sensitivity, long time of incubation, subjectivity and large amount of reagents. It is in this context that we propose to develop a new technology, which is free from the aforementioned limitations of the conventional hemagglutination assays. The proposed immunoassay is a sensitive and rapid method that utilizes inexpensive instrumentation. The Specific Aims of Phase II are: 1) To further explore all variables affecting the performance of the new blood typing detection assays and optimize the performance of the assay; 2) To design and assemble an �rototype of the device for performing of several blood typing assays simultaneously. The �rototype is intended to test the design of every technical element of the system before it is implemented in the final pre- production prototype; 3) To validate the detection assays for determination of blood groups (including weak D group and C, c, E, e and K antigens) and expected antibodies (reverse typing); To examine a statistically significant number of clinical samples for each assay, and carry out statistical analysis and demonstrate reproducibility of the obtained results; To compare performance of the conventional and newly developed assays. Significantly, the new method presents a general approach for enhancement and detection of agglutination of particles of different origin, including latex, silic microparticles, and biological cells.

描述（申请人提供）：本研究的长期目标是开发一种新型定量颗粒凝集技术，以提高血型分析的性能。传统的血凝血型分析存在灵敏度有限、时间长等严重缺陷。正是在这种背景下，我们建议开发一种新技术，该技术不受传统血凝测定的上述限制。使用廉价仪器的灵敏且快速的方法第二阶段的具体目标是： 1) 进一步探索影响性能的所有变量。新的血型检测分析并优化分析的性能；2) 设计和组装用于同时进行多种血型分析的设备原型。该原型旨在测试系统的每个技术元件的设计。在最终预生产原型中实施之前； 3) 验证血型（包括弱 D 型和 C、C、E、E 和 K 抗原）和预期抗体测定的检测分析（反向分型）；检查专家每个测定的大量临床样本，并进行统计分析并证明所获得结果的可重复性；为了比较传统和新开发的测定的性能，新方法提供了增强和检测颗粒凝集的通用方法。不同来源的材料，包括乳胶、硅微粒和生物细胞。